NOS2 and breast cancer: Endogenous inhibitor of NOS—ADMA—substantially increased (Fig. 2f) only in the late phase of metastasis (3–4 weeks after cancer cell inoculation), suggesting decreased NOS activity in the late metastatic phase of breast cancer progression.